Company Profile

Axonova Medical LLC
Profile last edited on: 4/20/2023      CAGE: 7EM09      UEI: DLUMA6JAZ1K4

Business Identifier: Re-creation of lost/damaged neural circuitry following neurological injury or disease: Peripheral nerve grafts
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3401 Grays Ferry Avenue Bldg 212-131
Philadelphia, PA 19146
   (269) 615-6632
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

Focused on potentially repairing with peripheral nerve grafts what are currently untreatable nerve, spinal cord and brain injuries as well as reversing the devastating consequences of neurodegenerative diseases such as Parkinson’s disease, Axonova Medical - currently resident in JPod Philadelphia and a spin-off from University of Pennsylvania - is working on development of a disruptive technology that is designed effectively recreate lost or damaged neural circuitry following neurological injury or disease. Nervous system demage requires the restoration of connectivity. Simply replacing nerve cells simply is insufficient unless they are connected to one another or to target tissues (e.g., muscle) by specialized fibers: designated axons. Related work in the space to date has so far failed to grow axons over long, clinically relevant distances as well as to guide their growth to the appropriate target tissue. Axonova is addressing both those previous failures. If successful the firm's could tackle surgical reconstruction of major peripheral nerve injury (PNI) following trauma or tumor resection and, potentially, be employed in addressing Parkinson’s disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NIH $250,421
Project Title: Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons.
2022 2 NIH $3,143,011
Project Title: Generation of Tissue Engineered Nerve Grafts from Galsafe Porcine Neurons

Key People / Management

  Harry Ledebur -- President and CEO

  D Kacy Cullen -- Founder

  Kritika Katiyar -- Director, R&D

  Douglas H Smith -- Founder

Company News

There are no news available.